Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJ5B | ISIN: KYG4672N1198 | Ticker-Symbol: H7T2
Frankfurt
27.06.25 | 08:07
2,440 Euro
-2,40 % -0,060
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
HUTCHMED CHINA LIMITED Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
2,4402,74012:33

Aktuelle News zur HUTCHMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.06.HUTCHMED (00013): NOMINATION COMMITTEE - TERMS OF REFERENCE1
20.06.HUTCHMED (00013): AUDIT COMMITTEE - TERMS OF REFERENCE1
10.06.HUTCHMED Ltd - 6-K, Report of foreign issuer2
10.06.Hutchmed führt neue Aktienoptionen und LTIP-Prämien ein2
10.06.Hutchmed introduces new share options and LTIP awards1
10.06.HUTCHMED (00013): GRANT OF SHARE OPTIONS UNDER SHARE OPTION SCHEME AND AWARDS UNDER LONG TERM INCENTIVE PLAN1
10.06.Hutchmed China Ltd - Grant of Share Options and Awards under LTIP-
HUTCHMED Aktie jetzt für 0€ handeln
05.06.Hutchmed new drug application accepted in China2
05.06.Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance-
05.06.CLSA: HUTCHMED Rating Kept at Outperform on Decent Savolitinib Research Data3
05.06.HUTCHMED Last Leaps ~5%, While INNOVENT BIO Falters; Application for Combination Therapy for RCC Accepted1
05.06.New Drug Application for INNOVENT BIO's Sintilimab Combination with HUTCHMED's Fruquintinib Accepted in CN1
05.06.HUTCHMED's NDA For Fruquintinib-sintilimab Combo In Renal Cancer Accepted By China's NMPA374BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) and Innovent Biologics, Inc. announced that the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment...
► Artikel lesen
05.06.HUTCHMED (China) Limited: HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma2
05.06.HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED AND INNOVENT JOINTLY ANNOUNCE NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WITH SINTILIMAB ...2
02.06.Hutchmed China Ltd - HUTCHMED Highlights SACHI Phase III Data at ASCO-
02.06.HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED HIGHLIGHTS SACHI PHASE III STUDY DATA PRESENTED AT THE 2025 ASCO ANNUAL MEETING1
30.05.HUTCHMED Ltd - 6-K, Report of foreign issuer2
30.05.HUTCHMED (00013): TOTAL VOTING RIGHTS-
30.05.Hutchmed China Ltd - Total Voting Rights-
Weiter >>
182 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1